NIPH Clinical Trials Search

JRCT ID: jRCT2041210087

Registered date:20/10/2021

A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedGeneralized Pustular Psoriasis (GPP)
Date of first enrollment11/11/2021
Target sample size131
Countries of recruitmentArgentina,Japan,Australia,Japan,Belgium,Japan,Bulgaria,Japan,Chile,Japan,China,Japan,Colombia,Japan,Croatia,Japan,Czech Republic,Japan,Egypt,Japan,France,Japan,Georgia,Japan,Germany,Japan,Greece,Japan,Israel,Japan,Italy,Japan,Korea,Japan,Malaysia,Japan,Mexico,Japan,Netherlands,Japan,Philippines,Japan,Poland,Japan,Russia,Japan,Singapore,Japan,South Africa,Japan,Spain,Japan,Taiwan,Japan,Thailand,Japan,Tunisia,Japan,Turkey,Japan
Study typeInterventional
Intervention(s)Drug: BI 655130 (Spesolimab) / Solution for infusion Drug: BI 655130 (Spesolimab) / Solution for injection


Primary OutcomeOccurrence of treatment emergent adverse events (TEAEs) up to week 252 of maintenance treatment
Secondary Outcome- The reoccurrence of a GPP flare defined by GPPGA - Time to first achievement of a GPPGA score of 0 or 1 (Patients received flare rescue treatment) - A GPPGA pustulation sub-score of 0 indicating no visible pustules, by visit - Change from baseline in Psoriasis Symptom Scale (PSS) score, by visit

Key inclusion & exclusion criteria

Age minimum>= 12age old
Age maximum<= 75age old
Include criteria1. Male or female patients who have completed the treatment period without premature discontinuation in the previous BI 655130 trial and are willing and able to continue treatment in the current trial 2. Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. 3. Signed and dated written informed consent and assent for the current trial 1368-0025, in accordance with ICH-GCP and local legislation prior to admission to the current trial
Exclude criteria1.Treatment with any restricted medication, or any drugs considered by the investigator likely to interfere with the safe conduct of the study since the last visit of the previous BI 655130 trial and during the screening period for the current trial 2.Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold Upper Limit of Normal (ULN) elevation in AST or ALT or alkaline phosphatase, or >2-fold ULN elevation in total bilirubin 3.Patients with congestive heart disease, as assessed by the investigator. 4.Relevant chronic or acute infections including human immunodeficiency virus or viral hepatitis. A patient can be re-screened if the patient was treated and is cured from acute infection. 5.History of allergy/hypersensitivity to a systemically administered trial medication agent or its excipients. 6.Any documented active or suspected malignancy at screening, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix. 7.Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Women who stop nursing before the study drug administration do not need to be excluded from participating; they should refrain from breastfeeding up to 16 weeks after the study drug administration

Related Information


Public contact
Name Yuji Takasu
Address 2-1-1, Osaki, Shinagawa-ku, Tokyo Tokyo Japan 141-6017
Telephone +81-120-189-779
Affiliation Boehringer Ingelheim
Scientific contact
Name Nobuko Yamada
Address 2-1-1, Osaki, Shinagawa-ku, Tokyo Tokyo Japan 141-6017
Telephone +81-120-189-779
Affiliation Boehringer Ingelheim